Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity (2013 - 2026)

Akebia Therapeutics (AKBA) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $362.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 16.87% year-over-year to $362.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 51.2% YoY), while the FY2025 annual figure was $376.6 million, up 70.65% from the prior year.
• Liabilities and Shareholders Equity eased to $362.5 million in Q1 2026 per AKBA's latest filing, from $376.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $541.8 million in Q1 2022 and bottomed at $207.1 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $324.5 million across 5 years, with a median of $310.2 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 52.12% — and 2025, when it soared 75.8%.
• Akebia Therapeutics' Liabilities and Shareholders Equity stood at $356.1 million in 2022, then tumbled by 32.12% to $241.7 million in 2023, then dropped by 8.7% to $220.7 million in 2024, then soared by 70.65% to $376.6 million in 2025, then fell by 3.73% to $362.5 million in 2026.
• Business Quant data shows AKBA's Liabilities and Shareholders Equity at $362.5 million in Q1 2026, $376.6 million in Q4 2025, and $364.2 million in Q3 2025.